Sight Sciences (SGHT) Investor Presentation - Slideshow

Business Overview - The company's mission is to transform ophthalmology and optometry by targeting the underlying causes of prevalent eye diseases[5] - The company focuses on surgical glaucoma and dry eye, with products aimed at restoring natural functionality of diseased eyes[5,6] Market Opportunity - The U S Total Addressable Market (TAM) for surgical glaucoma is $6 billion with over 120,000 cases performed[7] - The U S TAM for dry eye is $10 billion with over 20,000 cases performed, and 86% of DED cases are associated with MGD[8] - The standalone MIGS segment represents a $5 billion U S market opportunity[8] Financial Performance - Q2 Revenue was $17 2 million, a 37% year-over-year increase[93] - Surgical Glaucoma revenue was $15 9 million, a 33% year-over-year increase[93] - Dry Eye revenue was $1 3 million, a 143% year-over-year increase[93] Products and Clinical Trials - OMNI is indicated for use in both combination cataract and standalone MIGS procedures for primary open-angle glaucoma (POAG)[15] - TearCare is indicated for patients with evaporative DED due to MGD[8] - The OLYMPIA RCT showed that a single use of TearCare successfully reduced signs and symptoms of DED within 2 weeks[60]